DiaSorin


Healthy Q2 and H1; resulting in consecutive guidance upgrade

04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."

Pages
57
Language
English
Published on
04/08/22
You may also be interested by these reports :
17/08/22
Considering the downward revision to the full-year outlook (in reported terms), due to external challenges like tougher FX, high inflation and supply ...

17/08/22
Demant reported soft Q2 results. While, like Sonova, the management also downgraded is full-year outlook, the brewing slowdown in the US hearing aid ...

16/08/22
After many quarters of nervousness/disappointments, Philips today announced a change in CEO, effective mid-October 2022. This was perhaps inevitable ...

16/08/22
Following Sonova and Demant’s guidance downgrades, there has been a panic across the board with all hearing aid stocks in our coverage down 4-14%. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO